Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
2018 · Blood · 1,009 citations
https://doi.org/10.1182/blood-2017-09-801498
R
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
693
Papers
19.5K
Citations
69
h-index
270
i10-index
Roland B. Walter is an academic researcher from Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Acute Lymphoblastic Leukemia research & Chronic Myeloid Leukemia Treatments. The author has an h-index of 69, co-authored 590 publications.
ORCID: 0000-0002-9268-3341Papers by this author
works2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
2021 · Blood · 681 citations
https://doi.org/10.1182/blood.2021013626
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
2019 · Journal of Clinical Oncology · 680 citations
https://doi.org/10.1200/jco.18.01600
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
2013 · Blood · 350 citations
https://doi.org/10.1182/blood-2013-06-506725
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia
2020 · JAMA Oncology · 342 citations
https://doi.org/10.1001/jamaoncol.2020.4600
Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
2019 · Blood · 86 citations
https://doi.org/10.1182/blood-2019-127977
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat